key: cord-0689751-qvwco1bc
authors: Lambiase, Pier D.
title: Pacing Through a Pandemic-Coping with the “Tip of the Iceberg”
date: 2021-11-07
journal: Heart Rhythm
DOI: 10.1016/j.hrthm.2021.11.008
sha: 96e46c8967fe33896d3e0071a225eda665e69652
doc_id: 689751
cord_uid: qvwco1bc

nan

The Covid-19 pandemic has presented a once in a generation challenge to our healthcare systems worldwide. In its early phases, confusion existed regarding modes of transmission, levels of infection control and risk to healthcare personnel. This combined with lack of resources for adequate PPE generated high levels of anxiety for medical teams and rationing of PPE in the early phase. Advise and local guidelines were changing on an almost daily basis with major challenges in procedural risk assessment in the absence of immediate PCR testing-COVID-19 positivity was assumed until proven otherwise. It is in this "febrile" atmosphere that many of us were performing EP and pacing procedures with limited information and high levels of anxiety.

By undertaking an ambitious worldwide retrospective survey of pacing procedures at this time Tovia-Brodie, et al have valiantly attempted to capture the outcomes of this early phase over the 1 st year from March 2020-2021 across essentially two COVID-19 waves providing important insights (1). They surveyed 53 centres from 13 countries (4 continents) providing data on 166 patients with active COVID-19 infection undergoing CIED procedures. The main indications included high grade/complete AV block (67.5% patients) or sick sinus syndrome (18.7% patients). There were high 30-day complication rates of 13.9% and correspondingly high 9.6% 180-day mortality rate. One leadless system patient had a lethal haemorrhagic complication arising from the procedure. As expected, mortality tracked with COVID-19 disease severity & C Reactive Protein levels ranging between 4.1% to 38.9% in mild to critical disease respectively. Mortality also increased with anesthesiologist involvement: ranging from 7.2% to 40% in patients receiving local & general anesthesia, respectively (p=0.007).

The use of PPE was also highly variable ranging from routine in all procedures during the pandemic in 22% centers, to only in positive or suspected COVID-19 cases in 53.1% centers. Surprisingly the level of PPE, although perceived as limiting operator ability, did not translate into greater complication rates, this may reflect a type II statistical error.

The complications and mortality most likely reflect the severity of COVID disease since C Reactive Protein levels were statistically significantly linked to these outcomes.

Anesthesiologist involvement was one of the strongest markers of adverse outcomes J o u r n a l P r e -p r o o f reflecting the teams' perception of patient instability and higher procedural risks. This combined with physical difficulties in device implant induced by PPE and the pressure to complete the procedure quickly almost certainly contributed to high implant complication rates.

The critical question is what we can learn to manage heart rhythm patients in future respiratory virus pandemics. Tovia-Brodie et al demonstrated 9.6% 180 day mortality rate-the exact cause of death is not specified. As all patients were suffering from COVID-19 infection, it is most likely a significant proportion died from complications of COVID-19 unrelated to their conduction disease. It was well documented that COVID-19 hospitalised patients' cardiovascular complications include acute heart failure in 3%-33%, cardiogenic shock (9%-17%), myocardial ischemia/infarction (0.9%-11%), venous thromboembolism and arterial thrombosis secondary to viral-mediated coagulopathy (2) . This begs the question as to whether the treatment of the bradyarrhythias with pacing would have significantly affected their prognosis, especially since 19% were implanted for sick sinus syndrome which may have been present pre-COVID-19 infection or an incidental finding due to COVID-19. How many of these implants arose simply as a response to intensive monitoring? In S.America, virtually all were emergency high grade AV block. Did sick syndrome arrhythmias cause significant haemodynamic compromise? It could have been a marker of autonomic dysfunction due to COVID-19 which tracks with disease severity (3). The differences between US and Europe are intriguing -in the US implantations were more in relatively young patients critically ill with COVID, in Europe less severe COVID in the elderly in whom the team believed an acute implantation was needed or atleast feasible. This may indicate that US (and Israel) were quite restrictive with implantation or may also reflect how well the denominator was collected.

All these patients were implanted with permanent systems in the context of infection which put them at risk of system related sepsis or endocarditis -there was a 17% device infection rate. Implanting temporary-permanent active fixation devices may have minimised this (4) . Although permanent systems are more expeditious to implant, avoiding the need for ongoing rhythm monitoring-it is yet to be determined if they are actually a safer & more cost effective option in this context. Leadless pacing may be a J o u r n a l P r e -p r o o f simpler approach but given the hemorrhagic death in this series, judicious implantation technique and vascular closure must be employed by experienced operators who are currently at a premium and cost-efficacy is undoubtedly a limiting factor.

More importantly, this survey represents the "tip of the iceberg" of cardiac patients who never reached hospital or avoided hospital for fear of COVID-19 infection despite the need for a procedure. In a British study, at the 1 st wave's peak, there were 28,969 acute cardiovascular deaths with an excess acute cardiovascular mortality of 8% (5) . The most frequent cause of acute cardiovascular death was stroke (35.6%), followed by acute coronary syndrome (24.5%), heart failure (23.4%), pulmonary embolism (9.3%) and cardiac arrest (4.6%). This reflects New York City which had the largest increase in ischemic heart disease deaths in the US early phase (6) . The COVID-19 pandemic inflated acute cardiovascular deaths, nearly half of which occurred in the community and most did not relate to COVID-19 infection suggesting there were delays to seeking help or the result of undiagnosed COVID-19. In a separate study, cardiac service activity decreased 60-100% compared with pre-pandemic levels in eight hospitals across China, Italy, and England (7) . In China, activity remained below pre-COVID-19 levels for 2-3 months even after easing lockdown and is still reduced in Italy and England. For total CVD , at 10% COVID-19 prevalence, modelling estimated direct impact of 31, 205 and 62, 410 excess deaths in England (RR 1.5 and 2.0, respectively), and indirect effect of 49, 932 to 99, 865 deaths. These excess non-Covid deaths were preventable as they were due to AF, heart failure, stroke and myocardial infarction.

Indeed, regarding primary prevention ICDs, the United Kingdom National Institute for Cardiovascular Outcomes Research (NICOR) reported 67% fewer ICD implants at the peak of the first wave than a year earlier, suggesting that the vast majority of primary prevention implants had been suspended. Alongside the individual centre reports of deaths on the waiting lists for ICD implantation (8), there was an increase in the number of out-of-hospital cardiac arrest patients during the pandemic.

A key lesson learned from the first wave is to prioritise prognostically important EP and device procedures as per HRS guidelines and ensuring these cases are performed with optimal infection control, even though the majority of the population is now vaccinated J o u r n a l P r e -p r o o f atleast in Europe and the US (9) . The challenge remains to both deliver care to the substantial backlog of patients created by the first 2 waves, with increasing focus on day case high throughput delivery models. Furthermore, there is the need to be prepared for combinations of influenza and COVID-19 infection -it is critical to maintain updated plans for patient prioritisation & flexible arrhythmia care delivery. In this way we can preserve life not only by vaccination & treating pneumonia but also by preventing avoidable arrhythmic and other cardiovascular disease deaths.

J o u r n a l P r e -p r o o f

Implantation of Cardiac Electronic Devices in Active COVID-19 Patients. Results from an International Survey

Alteration of Autonomic Nervous System Is Associated With Severity and Outcomes in Patients With COVID-19 Front

A Review of Temporary Permanent Pacemakers and a Comparison with Conventional Temporary Pacemakers

Place and causes of acute cardiovascular mortality during the COVID-19 pandemic

Cardiovascular Deaths During the COVID-19 Pandemic in the United States

Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic

Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force